Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP5541 in Chinese Participants With Advanced Prostate Cancer
NCT07339267Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jan 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abiraterone decanoate in prostate cancer (PCa), sponsored by Astellas Pharma. Primary endpoints: Maximum Concentration at 6 months, Time to Maximum Concentration at 6 months and 8 more. Started Jan 2026; status: recruiting.
02
Drugs
abiraterone decanoate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07339267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339267.